Research programme: factor Xa inhibitors - Bayer Healthare Pharmaceuticals

Drug Profile

Research programme: factor Xa inhibitors - Bayer Healthare Pharmaceuticals

Alternative Names: ZK 810388; ZK 814048; ZX 813039

Latest Information Update: 24 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Berlex Biosciences
  • Class Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 18 Sep 2007 Lead development is ongoing
  • 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals
  • 19 Apr 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top